Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Research & Development (2016 - 2021)

GT Biopharma (GTBP) has disclosed Research & Development for 9 consecutive years, with $6.3 million as the latest value for Q4 2021.

  • On a quarterly basis, Research & Development rose 2605.58% to $6.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $9.6 million, a 1877.53% increase, with the full-year FY2025 number at $3.5 million, down 40.12% from a year prior.
  • Research & Development was $6.3 million for Q4 2021 at GT Biopharma, up from $1.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.3 million in Q4 2021 to a low of -$6.2 million in Q4 2019.
  • A 5-year average of $742166.7 and a median of $425000.0 in 2017 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 112.52% in 2020, then skyrocketed 5225.0% in 2021.
  • GT Biopharma's Research & Development stood at $157000.0 in 2017, then skyrocketed by 1970.7% to $3.3 million in 2018, then plummeted by 289.73% to -$6.2 million in 2019, then surged by 103.78% to $233000.0 in 2020, then soared by 2605.58% to $6.3 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Research & Development are $6.3 million (Q4 2021), $1.0 million (Q3 2021), and $639000.0 (Q2 2021).